ReviewFrontiers in microbiology2016
Mycoplasma bovis: Mechanisms of Resistance and Trends in Antimicrobial Susceptibility.
Review in Frontiers in microbiology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 1 synthesis or guideline pooled it, 115 citations in OpenAlex.
- Use of recombinant proteins for the diagnosis and prevention ofFrontiers in veterinary science · 2024Pooled it
- Serological Detection of Antibodies AgainstVeterinary sciences · 2026Article
- Potential Host-Directed Mechanisms ofVeterinary sciences · 2026Article
- Integrated meta-analysis and sentinel surveillance: Global prevalence and risk factors forOne health (Amsterdam, Netherlands) · 2026Article
- The Phenotypic Divergence and Potential Microevolution of a DominantMicroorganisms · 2026Article
- Isolation, Identification, and Molecular Characterization ofPathogens (Basel, Switzerland) · 2026Article
- Investigating bronchoalveolar lavage fluid cytology in relation to pathogen identification and consolidation depth in calves.Journal of veterinary internal medicine · 2026Article
- Utility of a freehand frameless navigation system in computed tomography-assisted ventral bulla osteotomy for otitis media in calves.PloS one · 2026Article
- Article
- Review and comprehensive analysis of knowledge, tools, and implementation gaps for the control of contagious bovine pleuropneumonia.BMC veterinary research · 2025Review
- Fusion membrane proteins derived subunit vaccine candidates effectively protect against Mycoplasma bovis challenge in mice.BMC veterinary research · 2025Article
- Emergence of Novel Fluoroquinolone Resistance Mutations in Mycoplasma bovis, China, 2008-2023.Emerging infectious diseases · 2025Article
- Immunoinformatic development of a multiepitope messenger RNA vaccine targeting lipoate protein ligase and dihydrolipoamide dehydrogenase proteins ofVeterinary world · 2025Article
- Alteration in Tracheal Morphology and Transcriptomic Features in Calves After Infection withMicroorganisms · 2025Article
- The Pathogenomics of the RespiratoryPathogens (Basel, Switzerland) · 2025Article
- Exploring Metal Ions as Potential Antimicrobial Agents to Combat Future Drug Resistance inMicroorganisms · 2025Article
- Genomic analysis of the 2017 Aotearoa New Zealand outbreak ofFrontiers in microbiology · 2025Article
- Phenotypic and Genotypic Analysis of Antimicrobial Resistance inPathogens (Basel, Switzerland) · 2024Article
- A Comprehensive Review of the Common Bacterial Infections in Dairy Calves and Advanced Strategies for Health Management.Veterinary medicine (Auckland, N.Z.) · 2024Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mycoplasma bovis is a cell-wall-less bacterium and belongs to the class Mollicutes. It is the most important etiological agent of bovine mycoplasmoses in North America and Europe, causing respiratory disease, mastitis, otitis media, arthritis, and reproductive disease. Clinical disease associated with M. bovis is often chronic, debilitating, and poorly responsive to antimicrobial therapy, resulting in significant economic loss, the full extent of which is difficult to estimate. Until M. bovis vaccines are universally available, sanitary control measures and antimicrobial treatment are the only approaches that can be used in attempts to control M. bovis infections. However, in vitro studies show that many of the current M. bovis isolates circulating in Europe have high minimum inhibitory concentrations (MIC) for many of the commercially available antimicrobials. In this review we summarize the current MIC trends indicating the development of antimicrobial resistance in M. bovis as well as the known molecular mechanisms by which resistance is acquired.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.